{"protocolSection": {"identificationModule": {"nctId": "NCT00855959", "orgStudyIdInfo": {"id": "D5259C00001"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients", "officialTitle": "An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler\u00ae and Pulmicort Respules\u00ae in Japanese Asthmatic Adult Patients (Open, Multicenter, Phase III Study)"}, "statusModule": {"statusVerifiedDate": "2011-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-04", "studyFirstSubmitQcDate": "2009-03-04", "studyFirstPostDateStruct": {"date": "2009-03-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-08-17", "resultsFirstSubmitQcDate": "2011-02-16", "resultsFirstPostDateStruct": {"date": "2011-03-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-02-16", "lastUpdatePostDateStruct": {"date": "2011-03-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Carlsson, Lars-Goran, MD, Medical Science Director, Est.Respiratory Brands", "oldOrganization": "AstraZeneca Pharmaceuticals"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 \u03bcg/day or 800 \u03bcg/day for 4 weeks in the observation period in Japanese adult asthmatic patients with age of 16 years or older."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Pulmicort Respules"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 108, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily", "interventionNames": ["Drug: Budesonide"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "Pulmicort Turbuhaler at a dose of 200 \u03bcg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)", "interventionNames": ["Drug: Pulmicort Turbuhaler"]}], "interventions": [{"type": "DRUG", "name": "Budesonide", "description": "Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks", "armGroupLabels": ["1"], "otherNames": ["Pulmicort"]}, {"type": "DRUG", "name": "Pulmicort Turbuhaler", "description": "Pulmicort Turbuhaler 200 \u00b5g, Dry powder inhaler, budesonide 200 \u00b5g/dose, 112 doses/Turbuhaler", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Morning Peak Expiratory Flow (mPEF)", "description": "Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}], "secondaryOutcomes": [{"measure": "Evening Peak Expiratory Flow (ePEF)", "description": "Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)", "description": "Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)", "description": "Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)", "description": "Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Use of Rescue Medication (Daytime)", "description": "Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Use of Rescue Medication (Night-time)", "description": "Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Use of Rescue Medication (Total)", "description": "Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Night-time Awakenings Due to Asthma Symptoms", "description": "Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV 1.0)", "description": "Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Forced Vital Capacity (FVC)", "description": "Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "timeFrame": "6 weeks"}, {"measure": "Number of Participants With Adverse Events (AEs)", "description": "Number of participants with AEs reported during the period on Pulmicort Respules", "timeFrame": "6 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures.\n* A minimum of 6 months documented history of asthma according to the JGL 2006 definition\n* Asthma patients under prescribed treatment with ICS at least 3 months before Visit 2.\n\nExclusion Criteria:\n\n* Current or previous tobacco smokers with a history of \\>= 10 pack-years\n* Use of \u03b2-blockers including eye drops\n* Clinically significant respiratory infection affecting the asthma, as judged by the investigator(s) within 4 weeks prior to visit 2\n* Intake of oral, rectal or parenteral GCS within 4 weeks prior to Visit 2", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lars-G\u00f6ran Carlsson, MD", "affiliation": "AstraZeneca R&D Lund", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Ichikawa", "state": "Chiba", "country": "Japan", "geoPoint": {"lat": 40.58333, "lon": 141.45}}, {"facility": "Research Site", "city": "Yokosuka", "state": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 35.28361, "lon": 139.66722}}, {"facility": "Research Site", "city": "Chiyoda", "state": "Tokyo", "country": "Japan"}, {"facility": "Research City", "city": "Hino", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.67306, "lon": 139.40028}}, {"facility": "Research Site", "city": "Setagaya", "state": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Research Site", "city": "Tachikawa", "state": "Tokyo", "country": "Japan"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Outpatients, male and female \u2265 16 years with stable asthma", "groups": [{"id": "FG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "108"}]}, {"type": "Patients Who Received Pulmicort Respules", "achievements": [{"groupId": "FG000", "numSubjects": "105"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Incorrect enrolment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "106"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.9", "spread": "13.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "73"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "33"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Morning Peak Expiratory Flow (mPEF)", "description": "Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "21.4"}]}]}]}, {"type": "SECONDARY", "title": "Evening Peak Expiratory Flow (ePEF)", "description": "Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.8", "spread": "18.1"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)", "description": "Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.018", "spread": "0.198"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)", "description": "Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.022", "spread": "0.185"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)", "description": "Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.039", "spread": "0.346"}]}]}]}, {"type": "SECONDARY", "title": "Use of Rescue Medication (Daytime)", "description": "Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "puffs", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.017", "spread": "0.160"}]}]}]}, {"type": "SECONDARY", "title": "Use of Rescue Medication (Night-time)", "description": "Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "puffs", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.044", "spread": "0.220"}]}]}]}, {"type": "SECONDARY", "title": "Use of Rescue Medication (Total)", "description": "Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "puffs", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.061", "spread": "0.317"}]}]}]}, {"type": "SECONDARY", "title": "Night-time Awakenings Due to Asthma Symptoms", "description": "Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "awakenings", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.004", "spread": "0.165"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV 1.0)", "description": "Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.079", "spread": "0.244"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC)", "description": "Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.105", "spread": "0.283"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events (AEs)", "description": "Number of participants with AEs reported during the period on Pulmicort Respules", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Pulmicort Turbuhaler and Pulmicort Respules", "description": "4 weeks treatment with either Pulmicort Turbuhaler at a dose of 400 \u03bcg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 108, "otherNumAffected": 7, "otherNumAtRisk": 105}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 105}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Helicobacter", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}